Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Home
/
update
/
details

Myriad Genetics and Flatiron Health Collaborate to Expand Access to Genetic Testing Through EMR Integration

NextEdge Admin

16 Oct 2024

2 min 8 sec

Flatiron Health,Genetic Testing,EMR Integration

Myriad Genetics, a leader in genetic testing and precision medicine, has partnered with Flatiron Health, a health tech company focused on oncology solutions, to enhance access to genetic testing through electronic medical record (EMR) integration. This collaboration enables providers to order Myriad’s MyRisk® Hereditary Cancer Test and view results seamlessly within Flatiron’s OncoEMR® platform—the first hereditary cancer test integrated into OncoEMR.

Through this partnership, more than 4,200 providers across 800 community-based cancer care centers in Flatiron’s network can order, receive, and review MyRisk test results directly in their existing EMR workflows. This streamlined approach supports personalized care by providing clinicians with quick access to germline testing results at the point of care, minimizing administrative work and improving turnaround times.

“Our collaboration with Flatiron simplifies genetic testing within existing workflows, helping clinicians deliver personalized care,” said George Daneker Jr., MD, President and Chief Clinical Officer of Oncology at Myriad Genetics. “We are excited to explore further genomic testing integrations with OncoEMR to meet even more patient needs.”

Stephen Speicher, MD, Senior Medical Director at Flatiron Health, emphasized the value of the integration in advancing precision medicine: “By embedding MyRisk testing into OncoEMR, we help physicians efficiently access critical genetic information, improving patient outcomes and care delivery.”

The MyRisk integration is now available to all OncoEMR users.